188 related articles for article (PubMed ID: 38030318)
21. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Peffault de Latour R; Brodsky RA; Ortiz S; Risitano AM; Jang JH; Hillmen P; Kulagin AD; Kulasekararaj AG; Rottinghaus ST; Aguzzi R; Gao X; Wells RA; Szer J
Br J Haematol; 2020 Nov; 191(3):476-485. PubMed ID: 32449174
[TBL] [Abstract][Full Text] [Related]
23. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study.
Lee JW; Sicre de Fontbrune F; Wong Lee Lee L; Pessoa V; Gualandro S; Füreder W; Ptushkin V; Rottinghaus ST; Volles L; Shafner L; Aguzzi R; Pradhan R; Schrezenmeier H; Hill A
Blood; 2019 Feb; 133(6):530-539. PubMed ID: 30510080
[TBL] [Abstract][Full Text] [Related]
24. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.
Annane D; Pittock SJ; Kulkarni HS; Pickering BW; Khoshnevis MR; Siegel JL; Powell CA; Castro P; Fujii T; Dunn D; Smith K; Mitter S; Kazani S; Kulasekararaj A
Lancet Respir Med; 2023 Dec; 11(12):1051-1063. PubMed ID: 36958364
[TBL] [Abstract][Full Text] [Related]
25. [Japanese patient preferences between ravulizumab and eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria].
Ishiyama K; Usuki K; Ikezoe T; Gotoh A; Myren KJ; Tomazos I; Shimono A; Ninomiya H; Sakurai M; Nakao S; Nishimura JI
Rinsho Ketsueki; 2023; 64(1):9-17. PubMed ID: 36775313
[TBL] [Abstract][Full Text] [Related]
26. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
27. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
28. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
29. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
30. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
31. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
32. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
[TBL] [Abstract][Full Text] [Related]
33. A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going?
Griffin M; Kelly R; Pike A
Ther Adv Rare Dis; 2020; 1():2633004020959349. PubMed ID: 37180495
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
[TBL] [Abstract][Full Text] [Related]
35. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
36. Interim analysis of post-marketing surveillance of ravulizumab for paroxysmal nocturnal hemoglobinuria in Japan.
Usuki K; Ikezoe T; Ishiyama K; Kanda Y; Gotoh A; Hayashi H; Shimono A; Kitajima A; Obara N; Nishimura JI
Int J Hematol; 2023 Sep; 118(3):311-322. PubMed ID: 37477863
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
38. Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bresnahan R; Houten R; Greenhalgh J; Nevitt S; Mahon J; Beale S; Boland A; Bhattacharyya D; Dundar Y; McEntee J; Gandhi S; Fleeman N; Chaplin M
Pharmacoecon Open; 2023 Jul; 7(4):525-536. PubMed ID: 37195551
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U; Della Porta MG; Santini V; Zeidan AM; Komrokji RS; Shortt J; Valcarcel D; Jonasova A; Dimicoli-Salazar S; Tiong IS; Lin CC; Li J; Zhang J; Giuseppi AC; Kreitz S; Pozharskaya V; Keeperman KL; Rose S; Shetty JK; Hayati S; Vodala S; Prebet T; Degulys A; Paolini S; Cluzeau T; Fenaux P; Garcia-Manero G
Lancet; 2023 Jul; 402(10399):373-385. PubMed ID: 37311468
[TBL] [Abstract][Full Text] [Related]
40. Changes in Hematologic Lab Measures Observed in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors, Ravulizumab and Eculizumab: Real-World Evidence from a US Based EMR Network.
Fishman J; Kuranz S; Yeh MM; Brzozowski K; Chen H
Hematol Rep; 2023 Apr; 15(2):266-282. PubMed ID: 37092521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
